X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
sn‐38 (48) 48
sn-38 (45) 45
camptothecin - analogs & derivatives (42) 42
humans (35) 35
irinotecan (34) 34
oncology (26) 26
cpt-11 (25) 25
cancer (23) 23
index medicus (22) 22
camptothecin - pharmacokinetics (21) 21
male (19) 19
camptothecin - administration & dosage (18) 18
female (18) 18
pharmacokinetics (16) 16
animals (15) 15
antineoplastic agents, phytogenic - pharmacokinetics (14) 14
camptothecin (14) 14
pharmacology & pharmacy (13) 13
article (12) 12
camptothecin - pharmacology (11) 11
mice (11) 11
middle aged (11) 11
adult (10) 10
aged (10) 10
cpt‐11 (10) 10
antineoplastic agents, phytogenic - administration & dosage (9) 9
camptothecin - blood (8) 8
camptothecin - metabolism (8) 8
camptothecin - therapeutic use (8) 8
tumors (8) 8
analysis (7) 7
antineoplastic agents, phytogenic - blood (7) 7
antineoplastic combined chemotherapy protocols - therapeutic use (7) 7
camptothecin - adverse effects (7) 7
cell line, tumor (7) 7
neoplasms - drug therapy (7) 7
tumor cells, cultured (7) 7
active metabolite (6) 6
antimitotic agents (6) 6
antineoplastic agents (6) 6
care and treatment (6) 6
chemotherapy (6) 6
colorectal cancer (6) 6
colorectal neoplasms - drug therapy (6) 6
drug delivery systems (6) 6
drugs (6) 6
micelles (6) 6
topotecan (6) 6
xenograft model antitumor assays (6) 6
antineoplastic agents, phytogenic - therapeutic use (5) 5
area under curve (5) 5
chemistry, multidisciplinary (5) 5
colorectal-cancer (5) 5
drug therapy (5) 5
glucuronosyltransferase - genetics (5) 5
kinetics (5) 5
metabolites (5) 5
neoplasms (5) 5
phase-i (5) 5
therapy (5) 5
trial (5) 5
antineoplastic agents - pharmacology (4) 4
antineoplastic agents, phytogenic - metabolism (4) 4
antineoplastic agents, phytogenic - pharmacology (4) 4
camptothecin - toxicity (4) 4
cell lung-cancer (4) 4
chemical compounds (4) 4
chemistry, medicinal (4) 4
drug synergism (4) 4
expression (4) 4
irinotecan cpt-11 (4) 4
metabolism (4) 4
mice, inbred balb c (4) 4
neutropenia (4) 4
overexpression (4) 4
prodrugs - pharmacology (4) 4
strategy (4) 4
toxicity (4) 4
transporter (4) 4
tumor (4) 4
vehicles (4) 4
abridged index medicus (3) 3
aged, 80 and over (3) 3
angiogenesis (3) 3
antineoplastic agents - administration & dosage (3) 3
antineoplastic agents, phytogenic - adverse effects (3) 3
antineoplastic agents, phytogenic - chemistry (3) 3
antineoplastic agents, phytogenic - toxicity (3) 3
atp-binding cassette transporters - genetics (3) 3
atp-binding cassette transporters - metabolism (3) 3
breast-cancer (3) 3
camptothecin - chemistry (3) 3
cancer patients (3) 3
cell line (3) 3
cisplatin (3) 3
clinical pharmacokinetics (3) 3
colonic neoplasms - drug therapy (3) 3
digestive system diseases (3) 3
dna topoisomerase-i (3) 3
drug carriers (3) 3
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal Article
Journal Article
Journal Article
Cancer, ISSN 0008-543X, 10/2017, Volume 123, Issue 19, pp. 3843 - 3854
BACKGROUND Sacituzumab govitecan (IMMU‐132), an antitrophoblastic cell‐surface antigen (anti‐Trop‐2) humanized antibody‐SN‐38 conjugate, had encouraging... 
clinical trial | trophoblastic cell‐surface antigen (Trop‐2) | epithelial cancers | antibody‐drug conjugate | IMMU‐132 (sacituzumab govitecan) | SN‐38 | SN-38 | METABOLITES | SOLID TUMORS | ETIRINOTECAN PEGOL NKTR-102 | CLINICAL PHARMACOKINETICS | BREAST-CANCER | EZN-2208 | antibody-drug conjugate | ONCOLOGY | COLORECTAL-CANCER | THERAPEUTIC TARGET | IRINOTECAN | IMMU-132 (sacituzumab govitecan) | trophoblastic cellsurface antigen (Trop-2) | Neoplasms - metabolism | Humans | Middle Aged | Half-Life | Immunoconjugates - pharmacokinetics | Male | Response Evaluation Criteria in Solid Tumors | Immunoconjugates - administration & dosage | Glucuronosyltransferase - genetics | Antineoplastic Agents, Phytogenic - administration & dosage | Antibodies, Monoclonal, Humanized - administration & dosage | Time Factors | Antibodies, Monoclonal, Humanized - pharmacokinetics | Camptothecin - blood | Aged, 80 and over | Antigens, Neoplasm - metabolism | Adult | Camptothecin - administration & dosage | Female | Neutropenia - chemically induced | Antineoplastic Agents, Phytogenic - pharmacokinetics | Antineoplastic Agents, Phytogenic - adverse effects | Camptothecin - analogs & derivatives | Immunoconjugates - adverse effects | Camptothecin - pharmacokinetics | Antibodies, Monoclonal, Humanized - adverse effects | Camptothecin - adverse effects | Cell Adhesion Molecules - metabolism | Neoplasms - drug therapy | Irinotecan | Aged | Immunoglobulin G - metabolism | trophoblastic cell-surface antigen (Trop-2) | Usage | Care and treatment | Safety and security measures | Analysis | Epithelial tumors | Pharmacokinetics | Antibody-drug conjugates | Camptothecin | Antigens | Toxicity | Immunoglobulin G | Breast cancer | Pharmacology | Metastasis | Criteria | Patients | Cell surface | Metastases | Uridine | Safety | Solid tumors | Drug dosages | Cancer | Tumors | Half life | Neutropenia | Glucuronosyltransferase | Index Medicus | Abridged Index Medicus
Journal Article
Chinese Journal of Chemistry, ISSN 1001-604X, 11/2018, Volume 36, Issue 11, pp. 1035 - 1040
(20S)‐Camptothecin, irinotecan and SN‐38 were successfully synthesized by a photocatalyzed radical cascade cyclization from an N‐propargyl iodopyridinone and... 
ruthenium | irinotecan | radicals | camptothecin | photocatalysis | SN‐38 | SN-38 | ANTITUMOR AGENTS | (S)-CAMPTOTHECIN | ASYMMETRIC-SYNTHESIS | ISONITRILES | CANCER | CHEMISTRY, MULTIDISCIPLINARY | Radicals | Catalysis
Journal Article
Cancer, ISSN 0008-543X, 12/2013, Volume 119, Issue 24, pp. 4223 - 4230
Journal Article
Journal of Clinical Pharmacy and Therapeutics, ISSN 0269-4727, 10/2016, Volume 41, Issue 5, pp. 579 - 582
Summary What is known and objective We measured the levels of irinotecan and its active metabolite, SN‐38, in human milk after the administration of irinotecan... 
human milk | irinotecan | infant | lactation | SN‐38 | Human milk | Irinotecan | Infant | SN-38 | Lactation | CPT-11 | PHARMACOLOGY & PHARMACY | CANCER | CHEMOTHERAPY | Camptothecin - metabolism | Humans | Adult | Camptothecin - administration & dosage | Female | Milk, Human - metabolism | Camptothecin - analogs & derivatives | Antimitotic agents | Metabolites | Antineoplastic agents | Mass spectrometry | Milk
Journal Article
Particle & Particle Systems Characterization, ISSN 0934-0866, 12/2018, Volume 35, Issue 12, pp. 1800334 - n/a
Journal Article
Journal Article
Journal Article